Krilogy Financial’s Sarepta Therapeutics SRPT Stock Holding History

Krilogy Financial’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-18,845	Closed	-$399K	–	1140
2026 Q1	$399K	Sell	18,845 -9,137	-33%	-$177K	0.01%	651
2025 Q4	$638K	Buy	27,982 +17,409	+165%	+$367K	0.02%	472
2025 Q3	$197K	Buy	+10,573	New	+$188K	0.01%	824
2018 Q4	–	Sell	-300	Closed	-$48K	–	593
2018 Q3	$48K	Buy	+300	New	+$41K	0.01%	321
2018 Q1	–	Sell	-350	Closed	-$19K	–	810
2017 Q4	$19K	Sell	350 -200	-36%	-$10.6K	﹤0.01%	441
2017 Q3	$25K	Sell	550 -100	-15%	-$4K	0.01%	450
2017 Q2	$22K	Hold	650	–	–	0.01%	429
2017 Q1	$18K	Hold	650	–	–	0.01%	437
2016 Q4	$18K	Buy	650 +50	+8%	+$2.01K	0.01%	437
2016 Q3	$37K	Hold	600	–	–	0.01%	348
2016 Q2	$11K	Hold	600	–	–	﹤0.01%	519
2016 Q1	$12K	Buy	+600	New	+$10.5K	﹤0.01%	453
2015 Q4	–	Sell	-800	Closed	-$26K	–	587
2015 Q3	$26K	Buy	+800	New	+$27.1K	0.01%	281

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Krilogy Financial's SRPT Position: Q2 2026 in Review

Krilogy Financial sold out of Sarepta Therapeutics (SRPT) in Q2 2026, closing a stake of 18,845 shares — an estimated $399K sold.

Krilogy Financial first reported a position in SRPT in Q3 2015 and held it in 13 quarters. The position peaked at $638K in Q4 2025. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Krilogy Financial reported no remaining Sarepta Therapeutics position as of Q2 2026 after selling out during the quarter.
Krilogy Financial sold 18,845 Sarepta Therapeutics shares in Q2 2026, an estimated $399K.
Krilogy Financial first reported a position in Sarepta Therapeutics in Q3 2015 and held it in 13 quarters.
Krilogy Financial's Sarepta Therapeutics position peaked at $638K in Q4 2025.
324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Krilogy Financial's 13F filing for Q2 2026, filed 27 Jul 2026.